跳至主要内容
临床试验/NCT03665844
NCT03665844已完成不适用

Smart Sleep In-home Validation Extension Study

Philips Respironics2 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2018年8月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
61
试验地点
2
主要终点
The effects of the auditory stimulation delivered by the SmartSleep device in adults with shortened sleep schedules due to lifestyle as determined by changes in the cumulative (CSWA) or average slow-wave activity.

研究概览

简要总结

This study is a nonrandomized, unblinded, uncontrolled case series clinical trial validating the SmartSleep product, including SleepMapper app in the home setting. It is intended to provide data related to product use and cognitive testing incorporating a longer baseline period for comparison purposes. It will include adults (21-50 yr. old) who are working full time and report shortened sleep due to lifestyle. For the purposes of this study, shortened sleep is defined as sleeping at least 5 hrs. of sleep per night, and sleeping less than or equal to 7 hrs. at least 3 nights per week. Participants also increase their sleep duration by ≥ 1 hour on the weekends. In addition, participants report a sleep latency ≤ 30 minutes less than or equal to 3 nights per week. Participants are generally healthy individuals who have not been diagnosed with any sleep-related medical conditions. In addition, participants diagnosed with major organ system diseases or requiring oxygen therapy are excluded from participation. Up to 75 individuals will be consented in order to complete a total of 50 participants using a nonrandomized design. The study involves an initial screening visit followed by home use of the SmartSleep device with SleepMapper app. The home use will include an initial week of baseline use followed by 3 weeks of use with boost on. Study staff will contact participants after the first week of use as a reminder. Participants will be asked to complete a battery of cognitive tests upon wake up each morning. Participants will be asked to complete a question twice daily during the home use period. Additional phone calls may occur on an as needed basis if issues arise. The final visit will be an in facility visit in which all study equipment will be returned. The anticipated study duration will be up to 6 weeks (including the 4 weeks of use period).

详细描述

Study procedures

Visit 1 (Screening) Procedures (up to 2 hours):

Participants will be asked to report to the research site for a daytime visit. A detailed interview will be performed verifying eligibility criteria, as well as a review of work and non-work schedules. After a full explanation of the protocol and after all the participants' questions have been answered, they will be asked to sign the consent form.

Participants will complete the following baseline information:

Demographics Questionnaires Medical History Questionnaire Review of Current Medications Height, Weight, Head Measurements Cognitive Assessment training

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Able to provide informed consent
  • Live in the US
  • Able to read, write and speak English
  • Adult volunteers aged 21-50
  • Smartphone owner (iOS 9+ or Android 5.0+ OS)
  • Access to home Wi-Fi for syncing of SmartSleep data and cognitive testing
  • Working full time schedule [Note: Full time is considered a 32 hour work week start time at 7am or later]
  • Suffer from short sleep due to lifestyle
  • Gets less than 7 hours of sleep at least 3 days a week (via self-report)
  • Get at least 5 hours of sleep per night 7 nights a week (via self-report)
  • Gets 1 extra hour of sleep on the weekends (via self-report of extended nightly sleep or daytime nap)

排除标准

  • Individuals who self-report severe contact dermatitis or an allergy to silver
  • Diagnosed as having any of the following conditions (via self-report):
  • Sleep Apnea
  • Restless legs syndrome
  • Parasomnia
  • Epilepsy/Seizures
  • Diagnosed as having any major organ system disease such as congestive heart failure, neuromuscular disease, renal failure, cancer, chronic obstructive pulmonary disease, respiratory failure or respiratory insufficiency, or patients requiring oxygen therapy (via self-report)
  • High Risk of Obstructive Sleep Apnea (OSA) based on Questionnaire
  • Daily caffeine intake > 650 mg
  • History of moderate hearing loss (via self-report)
  • Currently working night shift or rotating shift
  • Head circumference <54 cm (21 in) or >66 cm (26 in)
  • Individuals who self-report taking longer than 30 minutes more than 3 times a week to fall asleep once they turn lights off
  • Individuals who self-report regularly taking sleeping pills (more than once per week), including prescription or over the counter (OTC) pills such as Ambien, Tylenol PM or Zzzquil
  • Pregnant (via self-report)
  • Employee of Philips or spouse of a Philips employee
  • Employee (or spouse of an employee) of a company that designs, sells, or manufactures sleep-related products
  • Not able to comply with study procedures

研究组 & 干预措施

SmartSleep Boost Off

Placebo Comparator

Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.

干预措施: SmartSleep Boost Off (Device)

SmartSleep Boost On

Active Comparator

Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.

干预措施: SmartSleep Boost On (Device)

结局指标

主要结局

The effects of the auditory stimulation delivered by the SmartSleep device in adults with shortened sleep schedules due to lifestyle as determined by changes in the cumulative (CSWA) or average slow-wave activity.

时间窗: 4 weeks

Efficacy will be evaluated based on the average of seven nights of use collecting baseline data compared to the average of twenty one nights of active SmartSleep, while in the home setting. SWA accumulation over Non-Rapid Eye Movement (NREM) sleep (CSWA) will be analyzed for each night in the active condition using as reference the average CSWA across baseline nights.

次要结局

  • Change in performance of the Psychomotor Vigilance Testing -Brief (PVT) correlated to the changes in CSWA over the trial period.(4 weeks)
  • Change in performance of the Matrix reasoning task (MRT) correlated to the changes in CSWA over the trial period.(4 weeks)
  • Change in sleepiness/alertness as measured by a 7 point scale correlated to the changes in CSWA over the trial period.(4 weeks)
  • Change in performance of the Digital Symbol Substitution Task (DSST) correlated to the changes in CSWA over the trial period.(4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验